Participated · Series C · May 2024

Aardvark Therapeutics, led by CEO Tien Lee, M.D., is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics that activate innate homeostatic pathways for metabolic diseases, inflammation, and other indications. Its lead compound, oral ARD-101, is a potent bitter taste receptor (TAS2R) pan-agonist that stimulates enteroendocrine cells of the digestive tract to release multiple gut-peptide hormones including GLP-1 and the satiety hormone cholecystokinin (CCK). ARD-101 has demonstrated an ability to reduce hunger when used alone or in combination with currently available GLP-1 therapies, and based on promising clinical data the FDA has granted the drug both Orphan Drug designation and Rare Pediatric Disease designation in Prader-Willi Syndrome. The company intends to use the Series C proceeds to complete the clinical trials required for regulatory approval of ARD-101 for hyperphagia in PWS and to demonstrate ARD-101’s complementary mechanism of action to current GLP-1 therapies in the treatment of obesity. Aardvark also plans to advance other pipeline programs with the financing. The company is based in San Diego, CA. Aardvark Therapeutics, led by CEO Tien Lee, M.D., is a San Diego-based clinical-stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for metabolic diseases. Its lead compound, ARD-101, is a first-in-class small molecule TAS2R pan-agonist that demonstrated safety in Phase 1 human trials. ARD-101 has shown beneficial effects in animal models of obesity, hyperphagia, diabetes, hyperlipidemia, and inflammation. The company plans to use newly raised capital to complete three Phase 2 clinical trials of ARD-101 and to advance several potential additional formulations for major indications. Founded in 2017, Aardvark has multiple other programs in its pipeline and has already partnered one program to Sorrento Therapeutics. The company completed a $29M Series B financing to fund these activities.

Participated · Series C · Dec 2023

Odyssey Therapeutics is a clinical-stage biopharmaceutical company developing medicines designed to precisely target disease pathology in autoimmune and inflammatory diseases. Since its founding in 2021, the company has built comprehensive drug discovery and development capabilities and advanced an internally discovered program through multiple clinical milestones. Odyssey has nominated multiple development candidates and established collaborations with pharmaceutical leaders and biotech innovators. Its portfolio includes internally discovered clinical and preclinical candidates intended to induce deep and durable remission across several inflammatory diseases with unmet need. The company plans to advance these programs toward important clinical milestones and translate scientific efforts into patient benefit. Odyssey recently completed a major financing to support progression of its clinical pipeline. Odyssey Therapeutics has built a discovery and development platform that merges computational and experimental technologies to identify modality-agnostic drug targets with high clinical potential. From its Boston headquarters, the company has advanced multiple programs from ideation to a portfolio of high-value product candidates within about two years of founding in late 2021. Odyssey is focused on bringing immunology and oncology therapeutics into clinical development, with several molecules that could enter the clinic in the next 12 months. Proceeds from financing will support advancement of multiple programs into clinical studies and continued investment in discovery to build a sustainable model for therapeutic innovation. The company emphasizes a capital-efficient model and aims to deliver safe and effective precision medicines to patients with serious diseases. Leadership includes founder and CEO Gary D. Glick, Ph.D., and an experienced board guiding clinical and company-building strategy. Odyssey Therapeutics, based in Boston, raised $168M in a Series B funding round led by General Catalyst. The round included participation from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. The company intends to use the funds to advance its portfolio of precision immunomodulators and oncology medicines. Its immunology and oncology portfolio encompasses eight declared programs initially focused on small molecule and protein therapeutics. Odyssey is building a discovery engine that integrates artificial intelligence and machine learning for molecular design, a chemistry platform encompassing proprietary covalent libraries targeting multiple amino acids, molecular glues and natural products, and a functional genomics platform for novel target discovery. Gary D. Glick, Ph.D. is Founder and Chief Executive Officer. Odyssey Therapeutics develops next-generation precision immunomodulators and oncology medicines using a discovery platform that combines target biology, medicinal and structural chemistry, physics-based molecular simulations, and AI/machine learning. The company was founded by Gary D. Glick, Ph.D., and is led by a team with a track record that includes helping bring more than 20 drugs to market. Odyssey intends to advance multiple pipeline programs and expand its discovery platform to broaden the druggable genome. Financially, the company completed a large Series A financing (see deal details). Odyssey is headquartered in Boston, with labs there, and is expanding its team to more than 90 scientists and staff. The company emphasizes selecting targets and therapeutic modalities aimed at maximizing clinical impact.

Participated · Series B · Apr 2023

Clear Street operates as a broker of securities and derivatives, serving clients with trading and related capital-markets services. According to documents reviewed by Bloomberg, the company generated approximately $940 million in net revenue in the twelve months ended 30 September 2025. It also posted a 2024 net profit of $89 million, a sharp turnaround from a $18 million loss in 2023. Executive Chairman Uriel Cohen and CEO Ed Tilly, the former chief executive of Cboe Global Markets, lead the company. Clear Street’s latest fundraising valued the business at $12 billion and paves the way for a near-term IPO filing. The firm has reportedly engaged Goldman Sachs, Morgan Stanley, and UBS as advisers for the prospective public listing.

Participated · Series B · Jul 2022

Agomab is focused on achieving disease modification by modulating fibrosis and regeneration in chronic indications such as fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. Its lead clinical candidate is AGMB-129, a gut-restricted oral small-molecule inhibitor of ALK5 (TGFβ1R) being evaluated in the Phase 2a STENOVA trial for fibrostenosing Crohn’s disease, with interim data expected in the first quarter of 2025. AGMB-447 is a lung-restricted inhaled small-molecule ALK5 inhibitor currently in a Phase 1 trial in healthy subjects and patients with idiopathic pulmonary fibrosis. AGMB-101 is a full MET agonistic antibody in the final stages of IND-enabling studies intended for development in liver cirrhosis. The company applies organ-restricted small molecules and high-affinity antibodies and highlights end-to-end R&D capabilities and a proven business-development track record. Proceeds from the recent financing will be used to advance clinical development across these programs. Agomab is a biology company focused on developing novel treatments to resolve fibrosis, repair tissue structure, and restore organ function. It combines new scientific insights with drug development to build a clinical pipeline of disease‑modifying programs in fibrotic diseases. Its lead candidate, AGMB-129, is a gut‑restricted small molecule ALK5 inhibitor that has started a Phase 2a STENOVA trial in Fibrostenosing Crohn’s Disease and received U.S. FDA Fast Track designation. A second TGFß‑targeting candidate, AGMB-447, is a Phase‑1‑ready lung‑restricted ALK5 inhibitor for idiopathic pulmonary fibrosis. AGMB-101 is an HGF‑mimetic cMET receptor agonist in IND‑enabling development for fibrotic disorders. The company is led by CEO Tim Knotnerus and recently raised $100M in Series C financing to support its clinical programs. Agomab is developing a portfolio of growth-factor-targeting antibodies and small molecule compounds that address hepatocyte growth factor (HGF) and transforming growth factor beta (TGF-ß) to repair tissues, resolve fibrotic processes and restore organ functions. Its lead candidate, AGMB-129, is a gastrointestinal-tract-restricted ALK-5 inhibitor currently in a Phase 1 trial in healthy volunteers for fibrostenotic Crohn’s disease. AGMB-447, a lung-restricted ALK-5 inhibitor for idiopathic pulmonary fibrosis, and AGMB-101, a full MET receptor agonist for organ failure, are in IND-enabling studies. The company recently added a partial MET-receptor agonist, AGMB-102, to its research pipeline. Agomab says the new capital will support clinical evaluation of its product candidates and further expand its pipeline and organization. The company is based in Ghent, Belgium. AgomAb Therapeutics develops highly specific monoclonal antibodies to modulate regenerative pathways, aiming to resolve inflammatory, metabolic, and fibrotic processes and induce structural tissue repair and functional organ recovery. Its lead candidate, AGMB-101, is an HGF-mimetic agonistic antibody targeting the MET receptor, developed using argenx’s SIMPLE Antibody™ platform, and is advancing through IND-enabling studies. The company reports preclinical studies have demonstrated AGMB-101’s potential across autoimmune, inflammatory, and fibrotic disorders. Proceeds from the Series B will fund clinical proof-of-concept studies for AGMB-101 and support expansion of the pipeline of regenerative pathway modulators. AgomAb has recently expanded its leadership team with hires for CMO, Chief Business Officer, and CFO to support clinical, corporate development, and financial activities. The company is headquartered in Ghent, Belgium. AgomAb Therapeutics develops HGF-mimetic agonistic monoclonal antibodies (“agomAbs”) intended to regenerate damaged and fibrotic tissues. Founded in 2017 and based in Ghent, Belgium, the company has generated a comprehensive preclinical package showing applications in fibrotic, inflammatory, autoimmune and degenerative diseases. Its platform aims to combine the regenerative and anti-fibrotic biology of HGF with the favorable drug-like properties of antibodies. AgomAb exercised an exclusive license with argenx for SIMPLE Antibodies™ developed under argenx’s Innovative Access Program. The company has assembled an experienced leadership team including CEO Tim Knotnerus, founder and CSO Paolo Michieli, and CDO Torsten Dreier. AgomAb is backed by an international syndicate of life-sciences venture investors and is positioned to advance its preclinical programs toward clinical development.

Participated · Series D · Feb 2022

Gauzy Ltd. focuses on research, development, manufacturing, and marketing of vision and light-control technologies, including smart glass and ADAS solutions. The company positions its products to support safe, sustainable, comfortable, and agile user experiences across multiple industries. Gauzy serves leading brands in over 50 countries through direct fulfillment and a certified and trained distribution channel. It is headquartered in Tel Aviv and maintains subsidiaries and entities in Germany, France, the United States, Canada, China, and Dubai. The article describes Gauzy as a world leader in smart glass and ADAS technologies. Gauzy develops and manufactures vision and light-control technologies—applying nanotechnologies like polymer dispersed liquid crystals and microscopic light-absorbing particles in films or directly on glass and polycarbonate. Its technologies enable modulation of transparency, opacity and translucency, and can help manage temperature to reduce energy costs. The company serves customers in construction, automotive, and aeronautics, and positions itself across R&D, design, production and final delivery. Gauzy also markets award-winning ADAS products, including next-generation camera-based smart mirrors, motion sensors, and optimized safety gates to improve visibility and blind-spot management. The company emphasizes sustainability, safety, comfort and wellbeing in its product applications. The article notes Gauzy is in a Series D funding round and received an initial investment from Hamilton Global Opportunities. Gauzy develops and manufactures suspended‑particle device (SPD) light‑control film and related enabling hardware (branded LCG®/SPD‑Smart) used to instantaneously change window tinting and create display functionality. Its products are sold through a distribution channel of over 70 certified industrial partners and direct fulfillment, and the company reports approximately $50 million in 2021 revenues. The combined Gauzy/Vision Systems entity holds over 60 patents, 20 product categories, five manufacturing sites, 14 global offices and about 480 employees. Key production assets include a material synthesis facility in Israel and an 11,000 sqm SPD production site near Stuttgart, Germany with capacity to produce 1,000,000 sqm of SPD material yearly. Gauzy’s customers and integrations include automotive OEMs, aircraft and marine OEMs, LG Display, Avery Dennison, BMW and others, and the technology has been used in tens of thousands of vehicles. Going forward Gauzy plans to expand architectural and mobility deployments, integrate Vision Systems’ electronics and control systems capabilities, and add greater intelligence to control systems and ADAS/APAS offerings. Gauzy develops and manufactures two commercial active light-control technologies—SPD (suspended particle device) and LC (liquid crystal)—which are embedded into LCG (Light Control Glass) for dynamic, user-controlled light control. The company operates a material synthesis facility in Israel and a custom SPD production line in Stuttgart, Germany, producing SPD emulsion and light-control film for automotive, aircraft, and architectural industries. Gauzy’s German production site is set within an 11,000 sqm property and is dedicated to producing 1,000,000 sqm of SPD material yearly. The company reports a global distribution network of over 60 certified partners and sales, marketing, and distribution sites in multiple US cities and China. Gauzy positions SPD as providing up to 99.5% light blocking for shading while maintaining view, and highlights reduced costs and shortened delivery times from its production techniques. The company plans to use advances in product development and high-volume production to expand serial implementation of LCG technologies by industrial players.